Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.5300 (-1.16%) ($11.5050 - $11.5300) on Tue. Dec. 27, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.88% (three month average) | RSI | 39 | Latest Price | $11.5300(-1.16%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.4% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.4% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(43%) IWC(42%) IWM(42%) IWN(40%) | Factors Impacting FOLD price | FOLD will decline at least -1.44% in a week (0% probabilities). XLU(-12%) VXX(-12%) VIXM(-12%) ARKG(-10%) TLT(-8%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.44% (StdDev 2.88%) | Hourly BBV | -1.2 () | Intraday Trend | 0% | | | |
|
Resistance Level | $12.04 | 5 Day Moving Average | $11.76(-1.96%) | 10 Day Moving Average | $11.94(-3.43%) | 20 Day Moving Average | $12.04(-4.24%) | To recent high | -9.3% | To recent low | 15.3% | Market Cap | $2.977b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |